ACADIA Pharmaceuticals

Youtube Subscribe

Open: 19.92 Close: 20.09 Change: 0.17

You don't have time to read all about ACADIA Pharmaceuticals Stock. An AI summarizes all the information for you.

Are looking for the most relevant information about ACADIA Pharmaceuticals? Investor spend a lot of time searching for information to make investment decisions in ACADIA Pharmaceuticals. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about ACADIA Pharmaceuticals are: Acadia, Pharmaceuticals, ACAD, Rett, Inc, stock, pharmaceutical, and the most common words in the summary are: acadia, pharmaceutical, stock, acad, inc, market, rett, . One of the sentences in the summary was: Acadia pharmaceuticals (acad) worth $3.3 bil (down $0), more valuable than …

Concept Map

Semantic Network

Stock Summary

ACADIA Pharmaceuticals Inc. focuses on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders and rare diseases. It offers NUPLAZID (pimavanserin).

Today's Summary

Acadia Pharmaceuticals Inc. (ACAD) stock price, quote & news - stock analysis. Acadia pharmaceuticals (acad) worth $3.3 bil (down $0), more valuable than first republic bank. Acadia.

Today's News

Acadia Pharmaceuticals Inc. (ACAD) stock price, quote & news - stock analysis. acadia pharmaceuticals inc. (acad) (acAD) Price Target $21.59 (7.47% upside) Analyst Consensus: Buy Stock Forecasts. Zacks: ACADIA Pharmaceuticals - ACAD - Stock Price Today - Zacks Is It Time to Buy ACAD? Shares are up today. Acadia Pharmaceuticals has announced the commercial launch of its Rett Syndrome drug Daybue (trofinetide). Acadia pharmaceuticals (acad) worth $3.3 bil (down $0), more valuable than first republic bank. Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) given Consensus Recommendation of “Hold” by Brokerages - defense world.com. Acadia Pharmaceuticals announces daybueide™ (trofinetide™) treatment is now available for Rett syndrome. Acadia Pharmaceuticals Announces Daybue™ (Trofinetide) Is Now Available For Rett Syndrome Treatment XM does not provide services to residents of the United States of America.

Stock Profile

"ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California."

Keywords

This document will help you to evaluate ACADIA Pharmaceuticals without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about ACADIA Pharmaceuticals are: Acadia, Pharmaceuticals, ACAD, Rett, Inc, stock, pharmaceutical, and the most common words in the summary are: acadia, pharmaceutical, stock, acad, inc, market, rett, . One of the sentences in the summary was: Acadia pharmaceuticals (acad) worth $3.3 bil (down $0), more valuable than first republic bank. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #acadia #pharmaceutical #stock #acad #inc #market #rett.

Read more →

Youtube Subscribe

---